 |
|
|
|
 |
|
|
| Article 1 to 10 out of 14 concerning YM BIOSCIENCES INC.
|
-
YM Bioscience reports Phase II data for nimotuzumab in metastatic colorectal cancer
(08/06/2008)
Overall Survival And Disease Control Outcomes, Coupled With Low Toxicity, Support The Continued Development Of The EGFR Antibody In Patients With Colorectal Cancer
YM BioSciences Inc. announced preliminary results obtained from its open-label, Phase II study (YMB1000-015) of nimotuzumab in patients with irinotecan-refractory, metastatic colorectal cancer (mCRC). The data are based on 58 evaluable patients of ...
-
YM Bioscience USA enrolls first patient in phase II trial of Nimotuzumab in children with inoperable, recurrent brain cancer
(02/19/2008)
YM BioSciences Inc. announced that its wholly-owned US subsidiary, YM BioSciences USA Inc. has enrolled the first patient in its Phase II trial investigating nimotuzumab in pediatric patients with recurrent diffuse intrinsic pontine glioma (DIPG), a ...
-
YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with brain cancer
(09/03/2007)
YM BioSciences Inc. announced that its wholly-owned US subsidiary, YM BioSciences USA Inc. has been cleared by the US Food and Drug Administration (FDA) to initiate a Phase II trial investigating nimotuzumab in pediatric patients with recurrent ...
-
Oncoscience and YM BioSciences Announce Completion of Patient Enrollment in Phase III Brain Cancer Trial of Nimotuzumab
(08/17/2007)
YM BioSciences Inc. announced that Oncoscience AG, its European partner for the development of the humanized EGFR-targeting monoclonal antibody, nimotuzumab, has recruited the 40th and final patient in its international phase III trial combining ...
-
YM BioSciences Initiates Patient Enrolment In Phase II Colorectal Cancer Trial With EGFR Antibody
(08/03/2007)
YM BioSciences Inc. announced that it has enrolled the first five patients within the 50-patient initial cohort of its Phase II trial with nimotuzumab in combination with irinotecan for the treatment of patients with colorectal cancer who have ...
-
YM BioSciences announces preclinical data confirming nimotuzumab binds to the EGF receptor and potentiates radiotherapy
(07/11/2007)
YM BioSciences Inc. jannounced that a study presented by investigators from Kinki University School of Medicine and Kyoto University at the 11th meeting of The Japanese Association for Molecular Target Therapy of Cancer held on July 5-6, 2007 ...
-
YM Biosciences Licenses Monoclonal Antibody, Nimotuzumab, to Daiichi Pharmaceutical for Japan
(08/02/2006)
YM BioSciences Inc. announced that its majority owned subsidiary, CIMYM BioSciences Inc., has licensed development and marketing rights in Japan for its anti-EGFR humanized antibody, nimotuzumab, to Daiichi Pharmaceutical Co., Ltd. (a wholly owned ...
-
YM BioSciences reports anti-EGFr drug nimotuzumab approved in India for treatment of head and neck cancer
(07/24/2006)
YM BioSciences Inc. reported that India's Drug Controller General has granted marketing approval to nimotuzumab, an anti-EGFr monoclonal antibody, for the treatment of head & neck cancer. Biocon Biopharmaceuticals Ltd, a joint venture between Biocon ...
-
Kalbe Farma Sets Up R&D Base in Singapore to Focus on Drug Development of Biopharmaceuticals
(05/29/2006)
Indonesian-listed pharmaceutical company, PT Kalbe Farma Tbk. (Kalbe Farma) officially opened its office for research coordination and licensing in Singapore. The company focuses on research and development of biopharmaceuticals and other innovative ...
-
YM BioSciences' partner, Oncoscience AG, cleared for Phase III trial in Germany with nimotuzumaby
(03/30/2006)
YM BioSciences Inc. announced that its partner, Oncoscience AG, has been cleared by the German regulatory authority for biological products, the Paul Ehrlich Institute, to initiate a Phase III trial of nimotuzumab in combination with radiation in ...
|
|
|
|
|
Top
